Table 1.
Distribution of cancer cases considered in the analysis (N = 1268) by period of diagnosis
| Diagnosis | Period of diagnosis | ||
|---|---|---|---|
| 1982–1991 | 1992–2001 | 2002–2011 | |
| Leukaemia | |||
| ALL | 181 | 253 | 190 |
| AML | 32 | 41 | 43 |
| CML | 5 | 5 | 7 |
| JMML | 2 | 3 | |
| MDS* | 1 | 2 | |
| Lymphoma | |||
| Hodgkin lymphoma | 2 | 62 | 52 |
| Non-Hodgkin lymphoma | 6 | 49 | 51 |
| Solid tumours | |||
| Neuroblastoma | 1 | 20 | 37 |
| Wilms tumours | 25 | 34 | |
| Soft tissue sarcomas | 7 | 35 | |
| Ewing sarcoma/PNET | 7 | 28 | |
| Osteosarcoma | 6 | 24 | |
| Germ cell tumours | 1 | 15 | |
| Retinoblastoma | 2 | 8 | |
| Liver tumours | 5 | 4 | |
| Malignant vascular tumours | 2 | 3 | |
| Adrenocortical carcinoma | 1 | 3 | |
| Other very rare entities | 2 | 9 | |
| CNS tumours | 2 | ||
| Total | 227 | 491 | 550 |
| Adverse event (n, % within analysed time period) | |||
| No event | 53 (23.3) | 261 (53.2) | 370 (67.3) |
| Treatment-related mortality | 104 (45.8) | 109 (22.1) | 68 (12.4) |
| Disease relapse/progression | 69 (30.4) | 112 (22.8) | 108 (19.6) |
| Secondary cancers | 1 (0.4) | 7 (1.4) | 3 (0.5) |
| Others** | 0 (0) | 2 (0.4) | 1 (0.2) |
| (25–75% IQR) | (25.0–26.3) | (15.5–18.9) | (6.4–11.5) |
| [min-max] | [24.1–29.6] | [13.2–19.8] | [5.0–15.8] |
| Alive at the time of evaluation, (n, % within the analysed time period) | 66 (29.1) | 282 (57.4) | 404 (73.4) |
Abbreviations: ALL – acute lymphoblastic leukaemia, AML – acute myeloblastic leukaemia, CML – chronic myeloid leukaemia, CNS – central nervous system, IQR – interquartile range, JMML – juvenile myelomonocytic leukaemia, MDS – myelodysplastic syndrome (* refractory anaemia with excess of blasts in transformation), PNET – peripheral neuroectodermal tumours.
** “Others” refers to parental refusal to treat a child (n = 2) and suicide (n = 1).